Luspatercept Significantly Reduces Red Blood Cell Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients With Lower-Risk Myelodysplastic Syndromes Enrolled in the MEDALIST Trial

Uwe Platzbecker1, Diana Dunshee2, Rami S. Komrokji1, Ghalam J. Mufli1, Guillermo Garcia-Manero1, René Buckstein1, Valeria Santini1, Maria Diaz Campelo1, Mikkael A. Sekeres1, Wendy L. See2, Kevin Tsai2, Alberto Risueño3, Jianguin Ma3, Martin Schwickart4, Anita Rampersad1, Jennie Zhang1, Abderrahmane Laadem1, Daniel Menezes2, Kyle J. MacBeth2, Peter G. Linde12, Joseph G. Reynolds12, Alan F. List3, Pierre Fenaux13,14

1. Houston, TX, USA; 2Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada; 3MDS Unit, Azienda Ospedaliera Universita' Cattolica, Rome, Italy; 4Hematology Department, University Hospital of Salamanca, Institute of Biomedical Research of Salamanca, Salamanca, Spain; 5Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA; 6Colburn Institute for Translational Research Europe, Seville, Spain; 7Corporation, Sunnybrook NJ, USA; 8Astellas Pharma, Cambridge MA, USA; 9Service d’Hematologie du Saint-Etienne, Hôpital St-Etienne, Assistance Publique-Hôpitaux de Paris, Paris, France; 10Unioversa Paris 7, Paris, France

ABSTRACT 2999

RESULTS

- Frequency of Mutations in Patients Treated With Luspatercept in the MEDALIST Trial, Classified by Response
- Frequency of Number of Mutations at Baseline in Responders and Non-Responders Treated With Luspatercept
- Acquition and Loss of Mutations by Week 25
- Change in Mutations
- Change in Myeloid:erythroid Precursor Ratio During Treatment with Luspatercept

DISCLOSURES

REFERENCES

CORRESPONDENCE
Uwe Platzbecker: uwe.platzbecker@medison.com hepdogp

DISCLOSURES
- UF: Celgene Corporation, Novartis – consulting, research funding; AKD: consulting, research funding; M.J. Celgene Corporation – employee, equity ownership; R.P.R. Celgene Corporation – employee, research funding; J.H. Celgene Corporation – employee, research funding; G.C. Celgene Corporation – employee, research funding.

DISCLOSURES

REFERENCES


Correspondence: Uwe Platzbecker; e-mail: uwe.platzbecker@medison.com hepdogp

DISCLOSURES
- UF: Celgene Corporation, Novartis – consulting, research funding; AKD: consulting, research funding; M.J. Celgene Corporation – employee, equity ownership; R.P.R. Celgene Corporation – employee, research funding; J.H. Celgene Corporation – employee, research funding; G.C. Celgene Corporation – employee, equity ownership; B.H. Celgene Corporation – employee, equity ownership; A.P. Celgene Corporation – contractor. A.P. Celgene Corporation – employee, equity ownership; N.C. Celgene Corporation – employee, research funding; B.S. Celgene Corporation – employee, equity ownership; J.M.C. Celgene Corporation – employee, research funding; S.D. Celgene Corporation – employee, equity ownership; A.M. Celgene Corporation – employee, research funding; J.H. Celgene Corporation – employee, research funding; R.R. Celgene Corporation – employee, equity ownership; S.R. Celgene Corporation – employee, research funding; A.B. Celgene Corporation – employee, equity ownership; I. Celgene Corporation – employee, research funding; S.D. Celgene Corporation – employee, equity ownership; A.W. Celgene Corporation – employee, equity ownership.

REFERENCES


Correspondence: Uwe Platzbecker; e-mail: uwe.platzbecker@medison.com hepdogp